Cancer
Developing first-in-class or best-in-class targeted therapies to
treat malignancies.
of High Unmet Medical Needs
Our research team is focused on the discovery of novel therapies for diseases with
high unmet medical needs - leveraging our platform technology and core competencies.
First research team from Korea to publish a Nature cover story
Experience with exporting / licensing deals - Combined total value of recent deals for Acelex (966.6 Billion Won) and CG-806 (4,874 Billion Won) is ~1.5 Trillion Won
Research driven workforce - 95% of CG Invites' workforce consists of life science professionals with Masters and Ph.D.s
Next-gen Biopharma leader - Moving into the future to become a biopharmaceutical R&D technology leader.